Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer

被引:18
作者
Dearing, Kristen R. [1 ]
Sangal, Ashish [2 ]
Weiss, Glen J. [1 ,2 ,3 ]
机构
[1] Canc Treatment Ctr Amer, Dept Clin Res, 14200 W Celebrate Life Way, Goodyear, AZ 85338 USA
[2] Canc Treatment Ctr Amer, Dept Med, Goodyear, AZ 85338 USA
[3] CRAB Clin Trials Consortium, Seattle, WA 98101 USA
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 5卷 / 02期
关键词
Maintenance therapy; Clinical trials; Non-small cell lung cancer; Molecular aberrations; Progression-free survival; Overall survival;
D O I
10.5306/wjco.v5.i2.103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this article is to review the role of maintenance therapy in the treatment of advanced non-small cell lung cancer (NSCLC). A brief overview about induction chemotherapy and its primary function in NSCLC is provided to address the basis of maintenance therapies foundation. The development of how maintenance therapy is utilized in this population is discussed and current guidelines for maintenance therapy are reviewed. Benefits and potential pitfalls of maintenance therapy are addressed, allowing a comprehensive review of the achieved clinical benefit that maintenance therapy may or may not have on NSCLC patient population. A review of current literature was conducted and a table is provided comparing the results of various maintenance therapy clinical trials. The table includes geographical location of each study, the number of patients enrolled, progression free survival and overall survival statistics, post-treatment regimens and if molecular testing was conducted. The role of molecular testing in relation to therapeutic treatment options for advanced NSCLC patients is discussed. A treatment algorithm clearly depicts first line and second line treatment for management of NSCLC and includes molecular testing, maintenance therapy and the role clinical trials have in treatment of NSCLC. This treatment algorithm has been specifically tailored and developed to assist clinicians in the management of advanced NSCLC. (c) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:103 / 113
页数:11
相关论文
共 33 条
  • [1] Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
    Barlesi, Fabrice
    Scherpereel, Arnaud
    Rittmeyer, Achim
    Pazzola, Antonio
    Tur, Neus Ferrer
    Kim, Joo-Hang
    Ahn, Myung-Ju
    Aerts, Joachim G. J. V.
    Gorbunova, Vera
    Vikstrom, Anders
    Wong, Elaine K.
    Perez-Moreno, Pablo
    Mitchell, Lada
    Groen, Harry J. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) : 3004 - +
  • [2] Adherence to oral antineoplastic agents by cancer patients: definition and literature review
    Bassan, F.
    Peter, F.
    Houbre, B.
    Brennstuhl, M. J.
    Costantini, M.
    Speyer, E.
    Tarquinio, C.
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2014, 23 (01) : 22 - 35
  • [3] Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
    Brodowicz, T
    Krzakowski, M
    Zwitter, M
    Tzekova, V
    Ramlau, R
    Ghilezan, N
    Ciuleanuf, T
    Cucevic, B
    Gyurkovits, K
    Ulsperger, E
    Jassem, J
    Grgic, M
    Pinar, S
    Szilasi, M
    Wiltschke, C
    Wagnerova, M
    Oskina, N
    Soldatenkova, V
    Zielinski, C
    Wenczl, M
    [J]. LUNG CANCER, 2006, 52 (02) : 155 - 163
  • [4] Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
    Camidge, D. Ross
    Kono, Scott A.
    Lu, Xian
    Okuyama, Sonia
    Baron, Anna E.
    Oton, Ana B.
    Davies, Angela M.
    Varella-Garcia, Marileila
    Franklin, Wilbur
    Doebele, Robert C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 774 - 780
  • [5] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Cappuzzo, Federico
    Ciuleanu, Tudor
    Stelmakh, Lilia
    Cicenas, Saulius
    Szczesna, Aleksandra
    Juhasz, Erzsebet
    Esteban, Emilio
    Molinier, Olivier
    Brugger, Wolfram
    Melezinek, Ivan
    Klingelschmitt, Gaelle
    Klughammer, Barbara
    Giaccone, Giuseppe
    [J]. LANCET ONCOLOGY, 2010, 11 (06) : 521 - 529
  • [6] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu, Tudor
    Brodowicz, Thomas
    Zielinski, Christoph
    Kim, Joo Hang
    Krzakowski, Maciej
    Laack, Eckart
    Wu, Yi-Long
    Bover, Isabel
    Begbie, Stephen
    Tzekova, Valentina
    Cucevic, Branka
    Pereira, Jose Rodrigues
    Yang, Sung Hyun
    Madhavan, Jayaprakash
    Sugarman, Katherine P.
    Peterson, Patrick
    John, William J.
    Krejcy, Kurt
    Belani, Chandra P.
    [J]. LANCET, 2009, 374 (9699) : 1432 - 1440
  • [7] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [8] Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
    da Silveira Nogueira Lima, Joao Paulo
    dos Santos, Lucas Vieira
    Sasse, Emma Chen
    Sasse, Andre Deeke
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) : 601 - 607
  • [9] Molecular Characterization May Be of PARAMOUNT Importance
    Dearing, Kristen R.
    Weiss, Glen J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (05) : 481 - 482
  • [10] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Fidias, Panos M.
    Dakhil, Shaker R.
    Lyss, Alan P.
    Loesch, David M.
    Waterhouse, David M.
    Bromund, Jane L.
    Chen, Ruqin
    Hristova-Kazmierski, Maria
    Treat, Joseph
    Obasaju, Coleman K.
    Marciniak, Martin
    Gill, John
    Schiller, Joan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 591 - 598